© 2007 - 2018 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi•Art,
and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.

Important Safety Statement: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.

Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.

Innovating patient-first cancer treatment is not just a tagline. It’s who we are, what we do and what makes us different. As the fight against cancer grows more complex, we continually introduce new thinking and fresh tools to push outcomes to entirely new levels.

Fill the form to see our roadmap video

At Accuray, we recognize navigating these challenges requires new thinking and fresh tools. The CyberKnife® and Radixact Treatment Delivery Systems already empower treatment teams with unique capabilities in both long-term cancer control and enhancing patient quality of life. Now, we are accelerating several patient-first innovations that will enable your practice to drive even greater improvements—making treatments shorter, safer, smarter and, ultimately, more effective.  

 Visit our website to learn more about our
patient-first technologies


An Inside Look at Patient-First Innovation